AR093512A1 - Derivados heterociclicos como moduladores de la actividad de cinasas - Google Patents
Derivados heterociclicos como moduladores de la actividad de cinasasInfo
- Publication number
- AR093512A1 AR093512A1 ARP130104220A ARP130104220A AR093512A1 AR 093512 A1 AR093512 A1 AR 093512A1 AR P130104220 A ARP130104220 A AR P130104220A AR P130104220 A ARP130104220 A AR P130104220A AR 093512 A1 AR093512 A1 AR 093512A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydropyrazinyl
- atoms
- independently
- hal
- dihydroxy
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- -1 benzoimidazolyl Chemical group 0.000 abstract 8
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003725 azepanyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 abstract 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente proporciona derivados de imidazol-piperidinilo de la fórmula (1) y su fabricación y uso para el tratamiento de enfermedades hiperproliferativas tales como el cáncer. Reivindicación 1: Compuestos de acuerdo con la fórmula (1), y sales farmacéuticamente aceptables, solvatos, solvatos de sales, tautómeros o estereoisómeros, incluyendo mezclas de los mismos en todas las proporciones, en donde: X¹ es N o CH; X² es CH₂ o NH; X³ es CH₂ o CO; X⁴ es O, CH₂ o NH; W es N o CH; R¹ es Ar o Het; R² es [C(R³)₂]ₚHet¹ o [C(R³)₂]ₚN(R³)₂; R³ es H o alquilo con 1, 2, 3 ó 4 átomos de C, que está opcionalmente sustituido; Ar es fenilo que está insustituido o mono, di o trisustituido con Hal, A, fenilo, CON(R³)₂, COOR³, NHCOA, NHSO₂A, CHO, COA, SO₂N(R³)₂, SO₂A, [C(R³)₂]ₚOR³, [C(R³)₂]ₚN(R³)₂ y/o [C(R³)₂]ₚCN; Het es furilo, tienilo, pirrolilo, imidazolilo, pirazolilo, oxazolilo, isoxazolilo, oxadiazolilo, tiazolilo, triazolilo, tetrazolilo, piridilo, pirimidilo, piridazinilo, pirazinilo, indolilo, isoindolilo, benzoimidazolilo, indazolilo o quinolilo, que está insustituido o mono, di o trisustituido con Hal, A, [C(R³)₂]ₚOR³, [C(R³)₂]ₚN(R³)₂, NO₂, CN, [C(R³)₂]ₚCOOR³, CON(R³)₂, NR³COA, NR³SO₂A, SO₂N(R³)₂, S(O)ₘA y/o O[C(R³)₂]qN(R³)₂; Het¹ es dihidropirrolilo, pirrolidinilo, azetidinilo, oxetanilo, tetrahidroimidazolilo, dihidropirazolilo, tetrahidropirazolilo, tetrahidrofuranoilo, dihidropiridilo, tetrahidropiridilo, piperidinilo, azepanilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, tetrahidropiranilo, piridilo o piperazinilo, que está insustituido o mono o disustituido con A; A es alquilo ramificado o no ramificado con 1 - 10 átomos de C, en donde uno o dos grupos CH y/o CH₂ no adyacentes pueden estar reemplazados por átomos de N, O y/o S y en donde 1 - 7 átomos de H pueden estar reemplazados por F o Cl; Hal es F, Cl, Br o I; cada m es independientemente 0, 1 ó 2; cada n es independientemente 0, 1 ó 2; cada p es independientemente 0, 1, 2, 3 ó 4; cada q es independientemente 2, 3 ó 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727298P | 2012-11-16 | 2012-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093512A1 true AR093512A1 (es) | 2015-06-10 |
Family
ID=49753470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104220A AR093512A1 (es) | 2012-11-16 | 2013-11-15 | Derivados heterociclicos como moduladores de la actividad de cinasas |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9580443B2 (es) |
| EP (1) | EP2920178B1 (es) |
| JP (1) | JP6386467B2 (es) |
| CN (1) | CN105051043B (es) |
| AR (1) | AR093512A1 (es) |
| AU (1) | AU2013344552B2 (es) |
| CA (1) | CA2890288A1 (es) |
| ES (1) | ES2620119T3 (es) |
| IL (1) | IL238825B (es) |
| WO (1) | WO2014078637A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4249471A3 (en) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| CN113956325A (zh) | 2014-06-13 | 2022-01-21 | 塔夫茨大学信托人 | Fap激活的治疗剂以及其相关用途 |
| US10736885B2 (en) * | 2015-10-07 | 2020-08-11 | Aiviva Biopharma, Inc. | Compositions and methods of treating dermal fibrotic disorders |
| CN105424842A (zh) * | 2015-12-29 | 2016-03-23 | 河北神威药业有限公司 | 一种阿法替尼及其有关物质的检测方法 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN108164548B (zh) * | 2016-12-07 | 2020-09-08 | 四川大学 | 嘧啶并吗啉衍生物及其制备方法和用途 |
| US20190388407A1 (en) * | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| EP3814347B1 (en) * | 2018-06-27 | 2023-05-03 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
| US20220144821A1 (en) * | 2019-01-29 | 2022-05-12 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Akt inhibitor |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| WO2022017448A1 (zh) | 2020-07-22 | 2022-01-27 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 |
| GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| CN100412066C (zh) | 2003-09-30 | 2008-08-20 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| CA2541989C (en) | 2003-10-24 | 2013-10-01 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
| BRPI0417498A (pt) | 2003-12-09 | 2007-05-29 | Us Gov Health & Human Serv | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006071819A1 (en) | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007072017A2 (en) | 2005-12-22 | 2007-06-28 | The Institute Of Cancer Research | Enzyme inhibitors |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| AR074072A1 (es) * | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| MY160468A (en) | 2009-02-11 | 2017-03-15 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| CA2803387C (en) | 2010-07-29 | 2017-12-05 | Bayard R. Huck | Cyclic amine azaheterocyclic carboxamides |
| BR112013012488B1 (pt) | 2010-11-24 | 2021-08-31 | Merck Patent Gmbh | Azetidinas quinazolina carboxamida, seus usos e seu processo de fabricação, composição farmacêutica, e kit |
| AU2012308681B2 (en) | 2011-09-12 | 2017-07-13 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
-
2013
- 2013-11-15 AU AU2013344552A patent/AU2013344552B2/en not_active Ceased
- 2013-11-15 US US14/432,316 patent/US9580443B2/en not_active Expired - Fee Related
- 2013-11-15 AR ARP130104220A patent/AR093512A1/es unknown
- 2013-11-15 JP JP2015542810A patent/JP6386467B2/ja not_active Expired - Fee Related
- 2013-11-15 CN CN201380069718.XA patent/CN105051043B/zh not_active Expired - Fee Related
- 2013-11-15 ES ES13802772.7T patent/ES2620119T3/es active Active
- 2013-11-15 CA CA2890288A patent/CA2890288A1/en not_active Abandoned
- 2013-11-15 EP EP13802772.7A patent/EP2920178B1/en not_active Not-in-force
- 2013-11-15 WO PCT/US2013/070261 patent/WO2014078637A1/en active Application Filing
-
2015
- 2015-05-14 IL IL23882515A patent/IL238825B/en active IP Right Grant
-
2016
- 2016-09-27 US US15/277,479 patent/US9850255B2/en not_active Expired - Fee Related
-
2017
- 2017-11-20 US US15/818,035 patent/US10287300B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20170015679A1 (en) | 2017-01-19 |
| US20180072757A1 (en) | 2018-03-15 |
| US9580443B2 (en) | 2017-02-28 |
| CN105051043A (zh) | 2015-11-11 |
| AU2013344552A1 (en) | 2015-04-23 |
| JP2016500065A (ja) | 2016-01-07 |
| AU2013344552B2 (en) | 2018-03-15 |
| US20150274750A1 (en) | 2015-10-01 |
| IL238825A0 (en) | 2015-06-30 |
| ES2620119T3 (es) | 2017-06-27 |
| US10287300B2 (en) | 2019-05-14 |
| IL238825B (en) | 2019-10-31 |
| US9850255B2 (en) | 2017-12-26 |
| JP6386467B2 (ja) | 2018-09-05 |
| CA2890288A1 (en) | 2014-05-22 |
| EP2920178A1 (en) | 2015-09-23 |
| EP2920178B1 (en) | 2016-12-21 |
| CN105051043B (zh) | 2017-05-10 |
| WO2014078637A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093512A1 (es) | Derivados heterociclicos como moduladores de la actividad de cinasas | |
| AR092365A1 (es) | Derivados de piridopirimidina | |
| AR090240A1 (es) | Derivados de triazolopirazina | |
| AR089945A1 (es) | DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe | |
| AR094981A1 (es) | Derivados de imidazopirimidinas | |
| AR087807A1 (es) | Derivados de benzonitrilo | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| NZ588830A (en) | Inhibitors of protein kinases | |
| AR092366A1 (es) | Derivados de (aza-)isoquinolinona | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR093017A1 (es) | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO | |
| AR088925A1 (es) | Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR089810A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR089527A1 (es) | Inhibidores de bromodominios | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| AR100333A1 (es) | Derivados de heterociclil-butanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |